Emergency Department Utilization by In-hospital Healthcare Workers after COVID-19 Vaccination

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

添加到收藏夹

Article Immunology

Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database

Mansour Tobaiqy et al.

Summary: The development of safe and effective vaccines against COVID-19 is crucial in the fight against the pandemic. Although some thrombotic adverse reactions were associated with the Oxford-AstraZeneca vaccine, the European Medicines Agency affirmed the vaccine's safety and effectiveness, with the benefits outweighing the risks. Conducting further analyses based on more detailed thrombotic adverse event reports may help evaluate causality with higher specificity.

VACCINES (2021)

添加到收藏夹

Article Medicine, General & Internal

Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System

Minji Jeon et al.

Summary: The study focused on investigating adverse events following immunization (AEFIs) for COVID-19 among healthcare workers (HCWs) who received the ChAdOx1 nCoV-19 vaccine. The majority of AEFIs reported were mild-to-moderate in severity, with older age groups experiencing fewer and less severe AEFIs. No serious events requiring hospitalization were reported, and most AEFIs resolved within a few days. The use of the Mobile Vaccine Adverse Events Reporting System (MVAERS) was found to be helpful in monitoring and sharing accurate information about vaccination against COVID-19.

JOURNAL OF KOREAN MEDICAL SCIENCE (2021)

添加到收藏夹

Article Medicine, General & Internal

Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience

Si Ho Kim et al.

Summary: The study in South Korea on healthcare workers receiving COVID-19 vaccinations showed that more adverse events were reported in ChAdOx1 nCoV-19 recipients compared to BNT162b2 recipients. However, most reported adverse events were mild to moderate in severity, emphasizing the importance of providing sufficient explanation and preparation for expected adverse events to promote widespread vaccination.

JOURNAL OF KOREAN MEDICAL SCIENCE (2021)

添加到收藏夹

Article Medicine, General & Internal

Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea

Seongman Bae et al.

Summary: A prospective survey conducted in South Korea on healthcare workers who received the first dose of two COVID-19 vaccines showed a higher rate of adverse reactions in the ChAdOx1 group compared to the BNT162b2 group. Females and younger age groups were more likely to experience vaccine-associated adverse reactions.

JOURNAL OF KOREAN MEDICAL SCIENCE (2021)

添加到收藏夹

Editorial Material Biochemistry & Molecular Biology

If the world fails to protect the economy, COVID-19 will damage health not just now but also in the future

Martin Mckee et al.

NATURE MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Maheshi N. Ramasamy et al.

LANCET (2020)

添加到收藏夹

Emergency Department Utilization by In-hospital Healthcare Workers after COVID-19 Vaccination

相关参考文献

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database

Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System

Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience

Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea

If the world fails to protect the economy, COVID-19 will damage health not just now but also in the future

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

导出引文

分享论文